HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. (2016)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood-2016-01-695098
PubMed Identifier: 27143257
Publication URI: http://europepmc.org/abstract/MED/27143257
Type: Journal Article/Review
Volume: 127
Parent Publication: Blood
Issue: 25
ISSN: 0006-4971